DAVID PARK to Aged, 80 and over
This is a "connection" page, showing publications DAVID PARK has written about Aged, 80 and over.
Connection Strength
0.046
-
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial. Nat Med. 2026 Mar; 32(3):992-1001.
Score: 0.027
-
Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites. Acta Neuropathol. 2021 05; 141(5):725-754.
Score: 0.019